Low serum Maresin-1 levels are associated with non-alcoholic fatty liver disease: a cross-sectional study

Abstract

Background Maresin-1 (MaR1) is an anti-inflammatory pro-resolving mediator and is considered a potential regulator of metabolic diseases. Non-alcoholic fatty liver disease (NAFLD) is a very common metabolic liver disease. However, little information is available on the relationship between MaR1 and NAFLD in humans. Therefore, the study explored the association between serum MaR1 levels and NAFLD. Methods A cross-sectional study was conducted in 240 Chinese people, including 116 non-NAFLD subjects and 124 NAFLD patients. Serum MaR1 levels were determined by enzyme-linked immunosorbent assay (ELISA). The association between MaR1 and NAFLD was assessed. Results Circulating MaR1 levels in NAFLD patients were markedly lower than those in non-NAFLD subjects (63.63 [59.87–73.93] vs 73.11 [65.12–84.50] pg/mL, P = 0.000). The percentages of patients with NAFLD gradually decreased with the increase of MaR1 quartiles (P < 0.001). Furthermore, serum MaR1 levels were positively associated with aspartate aminotransferase/alanine aminotransferase (AST/ALT), albumin, the albumin-globulin-ratio, and high-density lipoprotein cholesterol (HDL-C) (all P < 0.05) and negatively associated with body mass index (BMI), waist circumference, hip circumference, the waist-to-hip ratio, ALT, gamma-glutamyl transpeptidase (GGT), uric acid, triglyceride (TG), and fasting blood glucose (FBG) (all P < 0.05) after adjusting for sex and age. Binary logistic regression analysis revealed that serum MaR1 levels were significantly associated with NAFLD. Conclusions Circulating MaR1 levels were decreased in patients with NAFLD, and a negative correlation was identified between NAFLD and serum MaR1 concentrations. Decreased MaR1 might be involved in the development of NAFLD.

Effects of Sida corymbosa Leaf-Extract on the Lipid Profile of Carbon Tetrachloride-Injected Male Rats

“…Cholesterol synthesis in the treatment groups may have been inhibited by the presence of flavonoid, leading to decreased levels in the serum. Total cholesterol is one of the major parameters being determined when checking for abnormal lipid profiles and it is a risk factor to arteriosclerosis and other age related diseases [24][25]26]. Values represent means of triplicate results +/-SEM.…”

Eicosanoids and other oxylipins in liver injury, inflammation and liver cancer development

“…During the progression of NAFLD/ NASH in HFD models, levels of RvD1 and MaR1 significantly decreases with disease progression (Maciejewska et al, 2020). Lower circulating levels of MaR1 and RvD1 were also reported for NAFLD/NASH patients (Monserrat-Mesquida et al, 2020;Fang et al, 2021). RvD1, MaR1 as well as RvE1 are found to regulate lipid biosynthesis in hepatocytes (Jung et al, 2014;Rius et al, 2017;Jung et al, 2018;Oh et al, 2022).…”

“…While often defined for their pro-inflammatory functions, eicosanoids also play a role in resolution of inflammation by promoting M2 polarization of macrophages. Liver macrophages from mice lacking PGES1 or treated with EP4 antagonist are polarized towards M1 inflammatory profiles ( Nishizawa et al, 2018 ; Fang et al, 2021 ). In coculture systems using HCC cells, macrophages and T cells to mimic HCC microenvironment, M2 polarization is observed and found dependent on COX-2 expression ( Xun et al, 2021 ).…”

The diverse roles of macrophages in metabolic inflammation and its resolution

“…NAFLD was also associated with decreased serum MaR1 levels in humans ( Fang et al, 2021 ). Treatment with MaR1 reduces hepatic triglycerides, while increasing fatty acid oxidation gene expression and autophagy in ob/ob and DIO mice ( Laiglesia et al, 2018 ).…”